If you are a student, recent graduate or alumni interested in exploring a career in the biotechnology, pharmaceutical and life sciences industries, you are in the right place! Register today to start your job search and be contacted by employers nationwide looking for you! It only takes a few minutes and you will be on your way to the perfect job!
Tuesday, November 24, 2009
Amunix, Inc. and Versartis, Inc. announced today that the scientific journal Nature Biotechnology has published a comprehensive paper entitled “A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner.” The paper (http://dx.doi.org/10.1038/nbt.1588) describes the design of Amunix’s polypeptide sequence XTEN and presents preclinical data for Versartis’ product candidates VRS-859 as a monthly-dosed treatment for type 2 diabetes and VRS-317 as a monthly-dosed treatment for growth hormone deficiency.
The published data demonstrate that XTEN, a technology for half-life extension, can provide an effective means for prolonging the in vivo half-life of therapeutic peptides and proteins. With a longer half-life, patients have improved convenience and compliance with comparable efficacy to the drug without XTEN. XTEN is an unstructured recombinant polypeptide that is genetically fused to a peptide or protein. The XTEN sequence has been specifically designed to have low immunogenicity and good manufacturability, making it a generic platform technology applicable to a wide variety of peptide and protein therapeutics. The publication presents, for the first time, the example case of the exenatide peptide fused to XTEN, with a projected human half-life of 139 hours, and preclinical data on human growth hormone fused to XTEN with a half-life in monkeys of 110 hours.Read Full Article
posted in: California, News
Phoenix • Tucson • Palm Springs • Sacramento • San Diego • San Francisco • San Jose • Denver • Jacksonville • Miami • Orlando • Tampa • Atlanta • Chicago • Indianapolis • Kansas City • Louisville • New Orleans • Boston • Baltimore • Detroit • Grand Rapids • Minneapolis • Charlotte • Raleigh • Omaha • Atlantic City • Las Vegas • Reno • Buffalo • New York City • Cincinnati • Cleveland • Toledo • Tulsa • Portland • Philadelphia • Pittsburgh • Myrtle Beach • Memphis • Nashville • Austin • Dallas • Houston • San Antonio • Salt Lake City • Richmond • Seattle • Spokane
